News

ATCC Hires New Chief Commercial Officer

ATCC, the world’s premier biological materials management and standards organization, today announced it has hired Greg Ballish as its new Chief Commercial Officer. In his role, Ballish will head ATCC’s sales and marketing operations and partner with Ruth Cheng, Ph.D., Chief Innovation and Strategy Officer and Vice President of Corporate Development of ATCC, to oversee the corporate business and commercial center. As part of the executive leadership team, Ballish will focus on growing the company’s global footprint and reinforcing ATCC’s position as the de facto leader in biological resources.

“We are fortunate to add Greg’s considerable experience and inclusive management style to our executive team, and we look forward to seeing the impact of his commercial leadership,” said Raymond H. Cypess, DVM, Ph.D., Chairman and CEO of ATCC. “In his role, Greg will ensure that we remain a customer-centric organization and continue our commitment to exceeding expectations and fostering long-lasting partnerships with the institutions and organizations we serve.”

Ballish brings an extensive sales, marketing and operations background in the diagnostics, pharmaceuticals, medical devices, transfusion medicine and medical distribution markets to ATCC. He has guided organizations to top market share positions and held key leadership sales and marketing roles for companies including Abbott Labs, DuPont, Johnson & Johnson, LabCorp, LGC Clinical Diagnostics, Meridian Bioscience, Terumo BCT and the American Red Cross. Ballish holds a Master of Business Administration from Arizona State University and a Bachelor of Science in finance from Miami University.

Recent News

11/11/2025

Quoin Pharmaceuticals Announces Achievement of Topical Rapamycin Target Loadings for Two Proprietary Delivery Technologies

Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a late clinical stage specialty pharmaceutical company focused on rare and orphan diseases, today announced that the target loading concentrations for its two topical rapamycin delivery technologies have been successfully achieved. Specifically, a rapamycin loading concentration of 4% w/w has been achieved for Quoin’s proprietary topical

11/07/2025

Dan Myers Named Director of Virginia SBDC, Innovation Commercialization Assistance Program to Accelerate Tech-Driven Growth in the Commonwealth

The Virginia Small Business Development Center (SBDC) is pleased to announce that Dan Myers has been named the new Director for the Virginia SBDC – Innovation Commercialization Assistance Program (ICAP). Dan, a seasoned innovation strategist, will lead the Virginia SBDC – ICAP program that is designed to help Virginia small businesses turn ideas into commercial

11/06/2025

Luna Labs’ MedSim Product Lines Acquired by Integrated Medcraft

Integrated MedCraft LLC today announced it has acquired the TrueClot and Dislotech product lines from Luna Labs. This announcement is more than a successful transaction. It is an example of innovation being accelerated with the right strategic partner. We built Luna Labs with a clear mission to incubate, accelerate, and grow technologies to the point